--- title: "Mixed Q2 Prints Reveal Deep Divergence Across Uncategorized US Equities" type: "News" locale: "en" url: "https://longbridge.com/en/news/296906521.md" description: "Second-quarter 2026 financial results across a basket of US equities showed a stark divide, with GitLab and Sezzle delivering double-digit revenue growth while clinical-stage EyePoint plummeted." datetime: "2026-08-25T11:33:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296906521.md) - [en](https://longbridge.com/en/news/296906521.md) - [zh-HK](https://longbridge.com/zh-HK/news/296906521.md) generator: "portal-rs" --- # Mixed Q2 Prints Reveal Deep Divergence Across Uncategorized US Equities A broad basket of software, healthcare, and structured ETF products exhibited deep fundamental divergence at the tail end of the second-quarter 2026 earnings season, with strong double-digit growth from platforms like GitLab and Sezzle offset by severe sell-offs in pre-revenue and clinical-stage names, according to multiple analysts tracking the sectors. ### EyePoint Pharmaceuticals (EYPT.US) EyePoint shares plunged more than 60% in mid-August 2026 after the company announced its DURAVYU 2.7mg LUGANO Phase 3 trial in wet AMD failed to meet its primary endpoint. The firm reported a Q2 net loss of USD 94.5 million as R&D costs surged 51%. Still, the sell-off may be overdone, according to some analysts, as the company is targeting Q4 2026 for its second pivotal trial data readout. ### Hinge Health (HNGE.US) The digital physical therapy provider delivered record Q2 2026 revenue of USD 212.8 million, up 53% year-over-year. It generated a net income of USD 43.7 million, reversing a hefty USD 575.7 million loss in the same period last year. Hinge is also nearing a deal to acquire Cylinder Health to expand into gastroenterology care. ### Sherwin-Williams (SHW.US) Sherwin-Williams raised its full-year earnings forecast following a beat in its Q2 2026 results. Consolidated net sales reached USD 6.79 billion, a 7.5% year-over-year increase, while diluted EPS grew 14.3% to USD 3.43. The stock has outperformed recently, supported by USD 3.89 billion in sales from its Americas Group. ### GitLab (GTLB.US) GitLab reported fiscal Q1 2027 total revenue of USD 264.2 million, a 23% jump year-over-year, and posted a non-GAAP operating margin of 14%. The DevSecOps platform is targeting Q2 total revenue between USD 272 million and USD 274 million. In August, it rolled out its v19.3 update featuring new AI-focused upgrades for regulated enterprises. ### Mobileye (MBLY.US) Mobileye posted Q2 2026 earnings per share of USD 0.19, cruising past the USD 0.06 consensus estimate, with revenue clocking in at USD 508 million. However, the company faces leadership shifts as founder and CEO Shashua announced plans to step down, triggering a recent surge in call option volume. ### Sezzle (SEZL.US) The Buy Now, Pay Later firm saw its active user base surge 76.4% year-over-year to 854,000 in Q2 2026. Sezzle reported revenue of USD 149.68 million, beating estimates of USD 135.09 million, alongside an EPS of USD 1.13. The strong metrics prompted a rating upgrade to Buy by TD Cowen. ### Fermi Energia (FRMI.US) The pre-revenue energy firm recorded a Q2 2026 net loss of USD 25.81 million, and shares have trended downward in recent trading. Despite the widened loss, Fermi inked a 2.6-gigawatt power complex alliance with Hillcore Energy Capital and recently appointed industry veteran Lee McIntire as CEO. ### Defiance 2X Long DRAM ETF (DRAL.US) As capital continues to chase memory chip upside within the broader AI infrastructure build-out, DRAL provides leveraged 2x exposure to the DRAM market, capturing speculative fund flows attempting to time the memory cycle, according to market data. ### Defiance Nasdaq 100 Enhanced Options Income ETF (QQQY.US) Amid elevated tech volatility, QQQY continues to deploy daily credit call spreads on the Nasdaq-100 to generate weekly cash distributions, a strategy that is absorbing significant retail and institutional capital hunting for yield. ### Roundhill Innovation-100 0DTE Covered Call Strategy ETF (QDTE.US) QDTE is capitalizing on the explosive growth of zero-days-to-expiry (0DTE) options by selling out-of-the-money 0DTE calls on its Innovation-100 Index. The fund seeks to provide overnight exposure and daily income, highlighting the ongoing structural shift toward high-frequency derivative yield strategies. *This article does not constitute investment advice.* ### Related Stocks - [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md) - [HNGE.US](https://longbridge.com/en/quote/HNGE.US.md) - [SHW.US](https://longbridge.com/en/quote/SHW.US.md) - [GTLB.US](https://longbridge.com/en/quote/GTLB.US.md) - [MBLY.US](https://longbridge.com/en/quote/MBLY.US.md) - [SEZL.US](https://longbridge.com/en/quote/SEZL.US.md) - [FRMI.US](https://longbridge.com/en/quote/FRMI.US.md) ## Related News & Research - [GitLab Reports Q2 Earnings Next Week – Options Traders Set For 16% Move in GTLB Stock](https://longbridge.com/en/news/297324746.md) - [Sezzle (SEZL), Why Is The Latest Attention Raising Bigger Questions?](https://longbridge.com/en/news/297516648.md) - [Sezzle director Kyle M. Brehm sells 1,000 common shares worth $125,920](https://longbridge.com/en/news/297369485.md) - [Hinge Health director Elliott Robinson reports disposal of shares worth $30.71 million](https://longbridge.com/en/news/297234507.md) - [Fermi appoints Jeffrey Stein to audit committee after CEO McIntire resigns from panel](https://longbridge.com/en/news/297557480.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**